CGI Pharmaceuticals

CGI Pharmaceuticals, founded in 2000 out of Yale University, specialized in kinase drug discovery. The company was acquired by Gilead Sciences in July 2010. CGI's research laboratories, located in Branford, Connecticut, continue to operate under Gilead, focusing on the development of kinase inhibitors. The business primarily serves the pharmaceutical and biotechnology sectors, targeting diseases where kinase inhibitors can be effective. CGI Pharmaceuticals operated on a venture-backed business model before its acquisition, generating revenue through the development and licensing of its drug discovery technologies. The acquisition by Gilead allowed for continued research and development under a larger corporate umbrella, ensuring sustained innovation and contribution to the field of kinase drug discovery.

Keywords: kinase, drug discovery, Gilead Sciences, acquisition, research, biotechnology, pharmaceutical, inhibitors, Yale University, Branford.